AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs
After the FDA published draft guidance in June on developing drugs to help prevent migraines, two companies in this space are asking the agency to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
